Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
This article was originally published in The Pink Sheet Daily
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
You may also be interested in...
Eagerly Awaited Expanded Xtandi Label Should Accelerate Sales
Medivation had already expanded its enzalutamide sales force to complement partner Astellas’ team ahead of getting a new indication for the earlier, pre-chemotherapy prostate cancer setting. The expanded label now paves the way for reps to drop in on more urologists.
Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J&J
Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.
Deals Of The Week Looks At 2014 Takeout Targets
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.